2.74
0.05 (1.86%)
| Penutupan Terdahulu | 2.69 |
| Jumlah Dagangan | 503,210 |
| Harga / Jualan (P/S) | 1.32 |
| Harga / Buku (P/B) | 3.48 |
| Julat 52 Minggu |
| Margin Keuntungan | -65.27% |
| Margin Operasi (TTM) | -64.61% |
| EPS Cair (TTM) | -1.44 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 19.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 73.32% |
| Nisbah Semasa (MRQ) | 4.97 |
| Aliran Tunai Operasi (OCF TTM) | -32.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.19 M |
| Pulangan Atas Aset (ROA TTM) | -22.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.68% |
Sentimen Berita
-
Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System
2 hari lalu, 6:10AM
-
Pulmonx: 3 Key Takeaways for Long-Term Investors
08 Nov, 5:35PM
AISkor Stockmoo
| Nilai 30% | -3.3 |
| Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info | |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | 1.7 |
| Tiada aliran jelas sepanjang tahun lalu. Agak di bawah paras tertinggi 52 minggu. info | |
| Aliran menaik: harga di atas purata bergeraknya, dan purata itu sedang meningkat. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga naik. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.6 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini kebanyakannya positif. info | |
| Sentimen Pegangan info | NA |
| Wang Pintar 20% | 2.8 |
| Institusi bersih +3.45% daripada saham dalam pemfailan 13F terkini: 45 pemegang menambah, 67 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat -19.3% dari 31 Aug hingga 30 Oct 2026, 1 hari untuk tutup (FINRA). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak tidak sependapat, jadi skor dilemahkan. | |
| Tidak dikira dalam skor | |
| Di atas garis aliran jangka sederhana. info | |
| Harga tinggi berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran naik bagi ketiga-tiga tempoh. Momentum jangka pendek meningkat. info | |
| Harga hampir dengan paras sokongan. Paras sokongan dan rintangan menaik. info | |
| Skor Akhir | 0.14 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Pulmonx Corporation | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| LUNG | - | - | - | 3.48 | 0.1 |
| SMLR | 368 M | - | 7.48 | - | -0.4 |
| BSGM | 169 M | - | - | 36.58 | -0.1 |
| IINN | 19 M | - | - | 13.64 | -0.4 |
| PTHL | 15 M | - | - | 2.19 | 0.0 |
| RSLS | 4 M | - | 0.019 | 30.42 | -0.8 |
|
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.40% |
| % Dimiliki oleh Institusi | 90.83% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Primecap Management Co/Ca/ | 30 Sep 2026 | 4,408,431 |
| Soleus Capital Management, L.P. | 30 Sep 2026 | 3,088,323 |
| Almitas Capital Llc | 30 Sep 2026 | 1,080,038 |
| Parkman Healthcare Partners Llc | 30 Sep 2026 | 853,986 |
| Braidwell Lp | 30 Sep 2026 | 752,541 |
| D. E. Shaw & Co., Inc. | 30 Sep 2026 | 740,868 |
| Marshall Wace, Llp | 30 Sep 2026 | 660,466 |
| Acadian Asset Management Llc | 30 Sep 2026 | 522,987 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 67.43%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 45 | 4,687,719 |
| Berkurang | 67 | 3,808,268 |
| Baharu | 17 | 1,217,235 |
| Dijual habis | 24 | 578,840 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 787,512 | 1.0 |
| 15 Oct 2026 | 698,644 | 2.5 |
| 30 Sep 2026 | 802,733 | 3.2 |
| 15 Sep 2026 | 847,842 | 2.5 |
| 31 Aug 2026 | 976,237 | 2.6 |
| 14 Aug 2026 | 1,066,574 | 1.2 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Nov 2026 | Yahoo Finance |
Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside discussion at the Piper Sandler 38th Annual Healthcare… |
| 17 Nov 2026 | Yahoo Finance |
Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System
Study demonstrates potential to enable Zephyr® Valve treatment for selected severe COPD/emphysema patients previously ineligible due to collateral ventilationREDWOOD CITY, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in… |
| 08 Nov 2026 | Yahoo Finance |
Pulmonx: 3 Key Takeaways for Long-Term Investors
Gross margins above 75% and a narrowing path to cash flow breakeven give the turnaround real financial teeth. |
| 30 Oct 2026 | Yahoo Finance |
All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
| 28 Oct 2026 | Yahoo Finance |
Pulmonx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity… |
| 27 Oct 2026 | Yahoo Finance |
Pulmonx (LUNG) Q3 2026 Earnings Call Transcript
Revenue returned to growth while losses narrowed significantly on cost discipline. |
| 27 Oct 2026 | Yahoo Finance |
What Pulmonx (LUNG) Said on Its Q3 Earnings Call
Pulmonx (NASDAQ:LUNG) reported third-quarter revenue growth and a narrower loss as the company cited progress in rebuilding its U.S. sales organization, tightening expenses and advancing clinical programs intended to expand its market. Total worldwide revenue for the quarter ended Sept. 30 was $22… |
| 27 Oct 2026 | Yahoo Finance |
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of +26.92% and +3.75%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 27 Oct 2026 | Yahoo Finance |
Pulmonx Reports Third Quarter 2026 Financial Results
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2026 ended September 30, 2026. Recent Highlights… |
| 13 Oct 2026 | Yahoo Finance |
Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026
REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday… |
| 03 Sep 2026 | Yahoo Finance |
Pulmonx Shares Fall Following Recent Gains
Pulmonx (NASDAQ:LUNG) shares fell 10. 1% to $2… |
| 01 Sep 2026 | Yahoo Finance |
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025… |
| 26 Aug 2026 | Yahoo Finance |
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event? |
| Papar semua | ||
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |